Intellia Therapeutics Head office building

Press Releases

Intellia Therapeutics to Present at Evercore ISI 2nd Annual HealthCONx Conference

CAMBRIDGE, Mass. , Nov. 26, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present at the Evercore ISI 2 nd Annual HealthCONx Conference on
Read More

Intellia Therapeutics Announces Third Quarter 2019 Financial Results

On track to submit in mid-2020 an investigational new drug application for NTLA-2001 for the treatment of transthyretin amyloidosis Expects to nominate its first T cell receptor-directed engineered cell therapy development candidate for the treatment of acute myeloid leukemia by the end of 2019
Read More

Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2019 Earnings and Company Update

CAMBRIDGE, Mass. , Oct. 24, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present third quarter 2019 results and operational highlights in
Read More

Intellia Therapeutics Presents In Vivo and Ex Vivo Data at the 2019 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT)

First reported consecutive in vivo gene knockout and insertion achieves therapeutically relevant results in an alpha-1 antitrypsin deficiency mouse model Inserted highly active WT1-TCR into the endogenous TCR locus for potential improved treatments for hematological and solid malignancies
Read More

Intellia Therapeutics Announces Presentations at the 2019 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT)

CAMBRIDGE, Mass. , Oct. 16, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc . (NASDAQ: NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , announced one oral presentation and four poster
Read More

Intellia Therapeutics to Present at October Healthcare Investor Conferences

CAMBRIDGE, Mass. , Sept. 30, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present at the following upcoming healthcare conferences in
Read More

Arbitration Decision Affirms Intellia Therapeutics’ Interpretation of Licensing Agreement with Caribou Biosciences on the CRISPR/Cas9 Technology

Interim Award concluded all technology in dispute was exclusively licensed to Intellia   Parties must negotiate terms and payments to Intellia for Caribou’s use of the chemically modified guide RNAs CAMBRIDGE, Mass. , Sept. 26, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc.
Read More

Intellia Therapeutics Announces Second Quarter 2019 Financial Results and Company Update

NTLA-2001: Intends to submit an investigational new drug application in mid-2020 for lead in vivo program for the treatment of transthyretin amyloidosis On track to nominate first engineered cell therapy development candidate for the treatment of acute myeloid leukemia by end of 2019 Ends quarter
Read More

Intellia Therapeutics to Present at August Healthcare Investor Conference

CAMBRIDGE, Mass. , July 30, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present at the following upcoming healthcare conference in
Read More

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2019 Earnings and Company Update

CAMBRIDGE, Mass. , July 25, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present second quarter 2019 results and operational highlights in
Read More